Atomic structure of the cross-β spine of islet amyloid polypeptide (amylin)

Protein Science

Volumn 17, Issue 9, 2008, Pages 1467-1474

  Wiltzius, Jed J W ^a   Sievers, Stuart A ^a   Sawaya, Michael R ^a   Cascio, Duilio ^a   Popov, Dmitriy ^b   Riekel, Christian ^b   Eisenberg, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

Author keywords

Aggregation; Amylin; Amyloid; IAPP; Protein crystallization; Type 2 diabetes

Indexed keywords

AMINO ACID; AMYLIN; ASPARAGINYLASPARAGINYLPHENYLALANYLGLYCYLALANYLISOLEUCYLLEUCINE; SERYLSERYLTHREONYLASPARAGINYLVALYLGLYCINE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; X RAY DIFFRACTION;

AMINO ACID SEQUENCE; AMYLOID; CARRIER PROTEINS; COMPUTER SIMULATION; CRYSTALLIZATION; DIABETES MELLITUS, TYPE 2; DISULFIDES; HISTIDINE; HUMANS; HYDROGEN BONDING; ISLETS OF LANGERHANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SOLUBILITY; X-RAY DIFFRACTION;

EID: 50049095633     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.036509.108     Document Type: Article

References (44)

1. Azriel, R. and Gazit, E. 2001. Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J. Biol. Chem. 276: 34156-34161.
2. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921.
3. Cooper, G.J. 1994. Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease. Endocr. Rev. 15: 163-201.
4. Cooper, G.J.S., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., and Reid, K.B.M. 1987. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. 84: 8628-8632.
5. de Koning, E.J.P., Morris, E.R., Hofhuis, F.M.A., Posthuma, G., Höppener, J.W.M., Morris, J.F., Capel, P.J.A., Clark, A., and Verbeek, J.S. 1994. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. 91: 8467-8471.
6. Eanes, E. and Glenner, G. 1968. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16: 673-677.
7. Emsley, P. and Cowtan, K. 2004. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60: 2126-2132.
8. Esapa, C., Moffitt, J.H., Novials, A., McNamara, C.M., Levy, J.C., Laakso, M., Gomis, R., and Clark, A. 2005. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis. Biochim. Biophys. Acta 1740: 74-78.
9. Fox, N., Schrementi, J., Nishi, M., Ohagi, S., Chan, S.J., Heisserman, J.A., Westermark, G.T., Leckstrom, A., Westermark, P., and Steiner, D.F. 1993. Human islet amyloid polypeptide transgenic mice as a model of noninsulin-dependent diabetes mellitus (NIDDM). FEBS Lett. 323: 40-44.
10. Gazit, E. 2002. A possible role for p-stacking in the self-assembly of amyloid fibrils. FASEB J. 16: 77-83.
11. Goldsbury, C., Goldie, K., Pellaud, J., Seelig, J., Frey, P., Muller, S.A., Kistler, J., Cooper, G.J.S., and Aebi, U. 2000. Amyloid fibril formation from full-length and fragments of amylin. J. Struct. Biol. 130: 352-362.
12. Goldsbury, C.S., Cooper, G.J.S., Goldie, K.N., Muller, S.A., Saafi, E.L., Gruijters, W.T.M., Misur, M.P., Engel, A., Aebi, U., and Kistler, J. 1997. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119: 17-27.
13. Green, J., Goldsbury, C., Mini, T., Sunderji, S., Frey, P., Kistler, J., Cooper, G., and Aebi, U. 2003. Full-length rat amylin forms fibrils following substitution of single residues from human amylin. J. Mol. Biol. 326: 1147-1156.
14. Green, J.D., Goldsbury, C., Kistler, J., Cooper, G.J.S., and Aebi, U. 2004. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J. Biol. Chem. 279: 12206-12212.
15. Höppener, J.W.M., Ahren, B., and Lips, C.J.M. 2000. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343: 411-419.
16. Höppener, J.W.M., Nieuwenhuis, M.G., Vroom, T.M., Ahren, B., and Lips, C.J.M. 2002. Role of islet amyloid in type 2 diabetes mellitus: Consequence or cause? Mol. Cell. Endocrinol. 197: 205-212.
17. Hossain, P., Kawar, B., and El Nahas, M. 2007. Obesity and diabetes in the developing world - a growing challenge. N. Engl. J. Med. 356: 213-215.
18. Jayasinghe, S.A. and Langen, R. 2004. Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J. Biol. Chem. 279: 48420-48425.
19. Jayasinghe, S.A. and Langen, R. 2007. Membrane interaction of islet amyloid polypeptide. Biochim. Biophys. Acta 1768: 2002-2009.
20. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
21. Kajava, A.V., Aebi, U., and Steven, A.C. 2005. The parallel superpleated β-structure as a model for amyloid fibrils of human amylin. 348: 247-252.
22. Kapurniotu, A. 2001. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers 60: 438-459.
23. Kodali, R. and Wetzel, R. 2007. Polymorphism in the intermediates and products of amyloid assembly. Curr. Opin. Struct. Biol. 17: 48-57.
24. Konarkowska, B., Aitken, J.F., Kistler, J., Zhang, S., and Cooper, G.J.S. 2006. The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells. FEBS J. 273: 3614-3624.
25. Koo, B.W. and Miranker, A.D. 2005. Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid. Protein Sci. 14: 231-239.
26. Larson, J.L. and Miranker, A.D. 2004. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 335: 221-231.
27. Lawrence, M.C. and Colman, P.M. 1993. Shape complementarity at protein/ protein interfaces. J. Mol. Biol. 234: 946-950.
28. Luca, S., Yau, W.M., Leapman, R., and Tycko, R. 2007. Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry 46: 13505-13522.
29. Moriarty, D.F. and Raleigh, D.P. 1999. Effects of sequential proline substitutions on amyloid formation by human amylin20-29. Biochemistry 38: 1811-1818.
30. Nelson, R., Sawaya, M.R., Balbirnie, M., Madsen, A.O., Riekel, C., Grothe, R., and Eisenberg, D. 2005. Structure of the cross-β spine of amyloid-like fibrils. Nature 435: 773-778.
31. Nishi, M., Chan, S.J., Nagamatsu, S., Bell, G.I., and Steiner, D.F. 1989. Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. Proc. Natl. Acad. Sci. 86: 5738-5742.
32. Padrick, S.B. and Miranker, A.D. 2001. Islet amyloid polypeptide: Identification of long-range contacts and local order on the fibrillogenesis pathway. J. Mol. Biol. 308: 783-794.
33. Ritzel, R.A., Meier, J.J., Lin, C.-Y., Veldhuis, J.D., and Butler, P.C. 2007. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56: 65-71.
34. Saltiel, A.R. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517-529.
35. Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., Thompson, M.J., Balbirnie, M., Wiltzius, J.J.W., McFarlane, H.T., et al. 2007. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447: 453-457.
36. Schmitz, O., Brock, B., and Rungby, J. 2004. Amylin agonists: A novel approach in the treatment of diabetes. Diabetes 53: S233-S238.
37. Sumner Makin, O. and Serpell, L.C. 2004. Structural characterisation of islet amyloid polypeptide fibrils. J. Mol. Biol. 335: 1279-1288.
38. Tenidis, K., Waldner, M., Bernhagen, J., Fischle, W., Bergmann, M., Weber, M., Merkle, M.-L., Voelter, W., Brunner, H., and Kapurniotu, A. 2000. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 295: 1055-1071.
39. Thompson, M.J., Sievers, S.A., Karanicolas, J., Ivanova, M.I., Baker, D., and Eisenberg, D. 2006. The 3D profile method for identifying fibril-forming segments of proteins. Proc. Natl. Acad. Sci. 103: 4074-4078.
40. Tracz, S.M., Abedini, A., Driscoll, M., and Raleigh, D.P. 2004. Role of aromatic interactions in amyloid formation by peptides derived from human amylin. Biochemistry 43: 15901-15908.
41. Tycko, R. 2004. Progress towards a molecular-level structural understanding of amyloid fibrils. Curr. Opin. Struct. Biol. 14: 96-103.
42. Westermark, P., Wernstedt, C., Wilander, E., Hayden, D.W., O'Brien, T.D., and Johnson, K.H. 1987. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. 84: 3881-3885.
43. Westermark, P., Engstrom, U., Johnson, K.H., Westermark, G.T., and Betsholtz, C. 1990. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. 87: 5036-5040.
44. Yan, L.-M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A., and Kapurniotu, A. 2006. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. 103: 2046-2051.